DexCom/$DXCM
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
$DXCM
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
10,250
ISIN
US2521311074
Website
DexCom Metrics
BasicAdvanced
$32B
60.81
$1.33
1.50
-
Price and volume
Market cap
$32B
Beta
1.5
52-week high
$117.27
52-week low
$57.52
Average daily volume
3.1M
Financial strength
Current ratio
1.499
Quick ratio
1.275
Long term debt to equity
59.794
Total debt to equity
111.427
Interest coverage (TTM)
26.69%
Profitability
EBITDA (TTM)
857.8
Gross margin (TTM)
59.43%
Net profit margin (TTM)
12.90%
Operating margin (TTM)
15.25%
Effective tax rate (TTM)
26.77%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
5.98%
Return on equity (TTM)
23.72%
Valuation
Price to earnings (TTM)
60.813
Price to revenue (TTM)
7.691
Price to book
14.01
Price to tangible book (TTM)
14.79
Price to free cash flow (TTM)
55.466
Free cash flow yield (TTM)
1.80%
Free cash flow per share (TTM)
146.05%
Growth
Revenue change (TTM)
9.11%
Earnings per share change (TTM)
-13.32%
3-year revenue growth (CAGR)
17.27%
10-year revenue growth (CAGR)
30.71%
3-year earnings per share growth (CAGR)
28.60%
10-year earnings per share growth (CAGR)
33.39%
What the Analysts think about DexCom
Analyst ratings (Buy, Hold, Sell) for DexCom stock.
Bulls say / Bears say
DexCom reported a 27% year-over-year revenue increase in Q3 2023, reaching $975 million, and raised its full-year revenue guidance to approximately $3.575 to $3.6 billion. (benzinga.com)
The company announced a $500 million share repurchase program, indicating confidence in its financial position and future growth prospects. (benzinga.com)
DexCom's G7 Continuous Glucose Monitoring System received FDA approval in December 2022, with U.S. availability beginning in February 2023, potentially expanding its market share. (wikipedia.org)
In October 2023, DexCom's stock hit a new 52-week low, trading at $77.73, amid concerns over the FDA's establishment of a Digital Health Advisory Committee, which could lead to increased regulatory scrutiny. (benzinga.com)
The rising popularity of weight loss drugs in 2023 has put pressure on DexCom's stock, as these medications may reduce the need for continuous glucose monitoring devices. (benzinga.com)
DexCom received a warning letter from the FDA following inspections of its two key manufacturing facilities, which could impact production and sales. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
DexCom Financial Performance
Revenues and expenses
DexCom Earnings Performance
Company profitability
DexCom News
AllArticlesVideos
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
Business Wire·2 days ago
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders
Business Wire·1 week ago
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $32B as of June 20, 2025.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 60.81 as of June 20, 2025.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.